Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 73285-50-4 | MDL No. : | MFCD00133247 |
Formula : | C6H14ClNO4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZJIHMALTJRDNQI-VFQQELCFSA-N |
M.W : | 199.63 | Pubchem ID : | 13018787 |
Synonyms : |
|
Chemical Name : | (2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol hydrochloride |
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 5.0 |
Molar Refractivity : | 47.17 |
TPSA : | 92.95 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -8.23 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | -1.0 |
Log Po/w (WLOGP) : | -2.55 |
Log Po/w (MLOGP) : | -1.99 |
Log Po/w (SILICOS-IT) : | -1.76 |
Consensus Log Po/w : | -1.46 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -0.38 |
Solubility : | 82.9 mg/ml ; 0.415 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.47 |
Solubility : | 68.4 mg/ml ; 0.342 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | 1.51 |
Solubility : | 6420.0 mg/ml ; 32.1 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.02 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312 | UN#: | N/A |
Hazard Statements: | H302-H312-H332 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
34.5% | With potassium carbonate; triethylamine; potassium iodide; In N,N-dimethyl-formamide; at 70℃; for 7h; | Taking 0.59g (1.5mmol) 4 - (3 - chloro -4 - fluorophenyl amino) -7 - methoxy -6 - (3 - chlorine third oxygen radical) quinazoline (E ') dissolved in 3.0 ml DMF in, adding in 0.30g (1.5mmol) 1 - deoxynojirimycin hydrochloride, 0.24g (1.8mmol) K2 CO3 , 0.30g (1.8mmol) KI and 0.18g (1.8mmol) triethylamine. Heating to 70 C reaction 7 hours later, to take advantage of the heat filtering K2 CO3 And KI. Concentrating the reaction solution, the concentrated solution of water in 2 ml, stirring 1 hour, adjusted with ammonia water to pH 9 - 10, is continuously stirred for 1 hour. Filtering, by a small amount of methylene chloride wash the filter cake, the filter cake by silica gel column chromatography separation to obtain white powdery product E 0.27g, yield 34.5%. |
34.5% | With potassium carbonate; triethylamine; potassium iodide; In N,N-dimethyl-formamide; at 70℃; for 7h; | General procedure: Followed published procedure, 4a, 5a or 6a (0.5 mmol) were dissolved into DMF (3.0 mL), respectively, and the above were added to the mixture of 1-DNJHCl (1.5 mmol), potassium carbonate (1.8 mmol), potassium iodide (1.8 mmol) and triethylamine (1.8 mmol), then heated up to 70 C, and stirred for 7 h. The precipitated product was filtered and the filtrate was evaporated. The crude product was dissolved into water (2 mL), and stirred for 2 h, then adjusted pH~9-10 with 5% ammonia solution, further stirred for 1 h. The crude product was chromatographed by silica gel to afford residue 13a-13c as white powder (yield 26.4% ~ 30.2%). |
A235571[ 19130-96-2 ]
(2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol
Reason: Free-salt
[ 478922-47-3 ]
(3R,5S)-5-(Hydroxymethyl)pyrrolidin-3-ol hydrochloride
Similarity: 0.88
[ 1009335-36-7 ]
(3R,5R)-5-(Hydroxymethyl)pyrrolidin-3-ol hydrochloride
Similarity: 0.88
[ 23323-37-7 ]
(2R,3R,4R,5S)-6-(Octylamino)hexane-1,2,3,4,5-pentaol
Similarity: 0.81
[ 14216-22-9 ]
(2R,3R,4R,5S)-6-(Ethylamino)hexane-1,2,3,4,5-pentaol
Similarity: 0.81
[ 17366-48-2 ]
exo-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride
Similarity: 0.79
[ 478922-47-3 ]
(3R,5S)-5-(Hydroxymethyl)pyrrolidin-3-ol hydrochloride
Similarity: 0.88
[ 1009335-36-7 ]
(3R,5R)-5-(Hydroxymethyl)pyrrolidin-3-ol hydrochloride
Similarity: 0.88
[ 17366-48-2 ]
exo-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride
Similarity: 0.79
[ 198976-43-1 ]
(R)-Piperidin-3-ol hydrochloride
Similarity: 0.78
[ 64051-79-2 ]
3-Hydroxypiperidine Hydrochloride
Similarity: 0.78